The Centers for Disease Control and Prevention has announced intentions to award a sole source contract to Sanofi Pasteur Biologics, LLC for the purchase of services to perform a plaque titration to quantify the titer of Wetvax for the CDC smallpox stability program.
These services will assist the CDC laboratory by ensuring that potency testing is conducted using FDA qualified and validated vaccinia based potency assay on samples of Wetvax.
Additionally, these services help the laboratory in determining the characteristics of each of the lots of vaccine, including the final titer in Plaque Forming units per milliliter and the Lot Titer.
Sanofi Pasteur is the only validated potency test accepted by the FDA to perform a plaque titration to quantify the titer of Wetvax for the CDC smallpox stability program.
Source: FBO.gov (10478)